- |||||||||| Journal: Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities. (Pubmed Central) - Jun 16, 2023
Various natural compounds such as sarsapogenin, lycorine, biscoclaurine, vitamin B, glycyrrhizic acid, riboflavin, resveratrol and kaempferol, various vaccines and drugs such as AZD1222, mRNA-1273, BNT162b2, Sputnik V, and remdesivir, lopinavir, favipiravir, darunavir, oseltamivir, and umifenovir, resp., have been discussed comprehensively. We attempted to provide exhaustive information regarding the various prospective therapeutic approaches available in order to assist researchers and physicians in treating COVID-19 patients.
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Antibody responses to mRNA versus non-mRNA COVID vaccines among the Mongolian population. (Pubmed Central) - Jun 13, 2023
The BNT162b2 vaccine showed the highest level of antibody against SARS-CoV-2, followed by the BBIBP-CorV, Gam-COVID-Vac, and ChAdOx1 n-CoV-19 vaccines. The level of antibodies was increased in people infected with SARS-CoV-2 after vaccination, as compared to uninfected but vaccinated individuals.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
EVALUATION OF ANTIBODY RESPONSES TO SARS-COV-2 VACCINES IN PATIENTS WITH CKD (ePoster (Virtual Only)) - Jun 9, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2301;
Increasing age, history of CVD and lower eGFR were factors associated with a non-response. Potential differences between COVID-19 vaccines should be explored in prospective long-term follow-up studies.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-World Effectiveness of Four Types of COVID-19 Vaccines. (Pubmed Central) - May 27, 2023
All four vaccines evaluated in this study showed effectiveness against asymptomatic COVID-19 infection, symptomatic infection, hospitalization, and death. Furthermore, BNT162b2, BBIBP-CorV, and ChAdOx1 nCoV-19 induced high levels of immunology markers within one month of vaccination.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
FREQUENCY OF VACCINE-RELATED ADVERSE EVENTS IN PATIENTS WITH RHEUMATIC DISEASE () - May 19, 2023 - Abstract #EULAR2023EULAR_3322;
The adverse events according to the type of COVID-19 vaccine were the following: Sputnik-V 80%, Pfizer 76.6% and AstraZeneca 76.1%, without statistically significant difference between vaccine types...Providing this information to patients is important to improve vaccine acceptance. In addition, the administration of NSAID after the application of the vaccine could be proposed to reduce the presence of side effects.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Vaccination situation against COVID-19 in an adults cystic fibrosis center in Argentina (Poster Area) - May 9, 2023 - Abstract #ECFS2023ECFS_659;
There were no episodes of severe COVID-19 after administration of tixagevimab/cilgavimab. Given the need to complete the vaccination, heterologous schemes were used and although the COVID-19 pandemic is entering a control phase, boosters must be insisted on to maintain immunity in this population.
- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal: Tracking the COVID-19 vaccines: The global landscape. (Pubmed Central) - Apr 14, 2023
Thus, the present report provides data that will contribute to decisions making about the vaccine implementation plans of action for, not only our region but our country to support the fight against the COVID-19 global pandemic. COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; VLPs: Virus like particles; WHO: World Health Organization; E: Envelope; M: Membrane; S: Spike; N: Nucleocapsid; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; FDA: Food and Drug Administration; LNP: lipid-nanoparticle; AZD1222: ChAdOx1 nCoV-19; BNT162b2: Pfizer-BioNTech mRNA vaccine; mRNA-1273: Moderna vaccine; Ad26.COV2.S: Johnson and Johnson - Janssen's vaccine; Gam-COVID-Vac: Sputnik Vaccine; NVX-CoV2373: Novavax vaccine with Matrix-M
- |||||||||| Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal, Adverse events: Side effects of Sputnik V, Oxford-AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran. (Pubmed Central) - Apr 4, 2023
COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; VLPs: Virus like particles; WHO: World Health Organization; E: Envelope; M: Membrane; S: Spike; N: Nucleocapsid; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; FDA: Food and Drug Administration; LNP: lipid-nanoparticle; AZD1222: ChAdOx1 nCoV-19; BNT162b2: Pfizer-BioNTech mRNA vaccine; mRNA-1273: Moderna vaccine; Ad26.COV2.S: Johnson and Johnson - Janssen's vaccine; Gam-COVID-Vac: Sputnik Vaccine; NVX-CoV2373: Novavax vaccine with Matrix-M Compared to Sinopharm or Covaxin, the Sputnik V and Oxford-AstraZeneca vaccines were associated with a higher prevalence of SEs, a greater number of SEs per individual, and more severe SEs.
- |||||||||| CoronaVac / Sinovac, Bio Farma Indonesia, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
KIDNEY TRANSPLANTATION DURING THE THREE YEARS (2020-2022) OF COVID-19 PANDEMIC: SINGLE-CENTER EXPERIENCE () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1623;
Since 2022 we started to use remdesivir in recipients with symptomatic course of disease with positive results...There were no revealed any adverse effects of vaccination among our group. Conclusions In our experience, the current kidney transplant program seems viable and safe, even during periods of health emergencies.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
A COMPARISON OF GAM-COVID-VAC (SPUTNIK V) VACCINE IMMUNOGENICITY IN HEMODIALYSIS PATIENTS AND NON-RENAL SUBJECTS () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1616;
Introduction We report results on immunogenicity of the recombinant adenovirus (rAd) 26 and rAd5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by Gamaleya National Research Centre, Russia) in patients, receiving maintenance hemodialysis (HD)...Cellular response turned up to be more sustained over time in HD group. View Large Image Figure Viewer Download Hi-res image Download (PPT)
- |||||||||| CUMULATIVE INCIDENCE OF COVID-19 AND VACCINE PROFILES AMONG ASEAN PERITONEAL DIALYSIS POPULATIONS: A PRELIMINARY RESULT OF THE "InCoV-PD" STUDY GROUP () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1610;
View Large Image Figure Viewer Download Hi-res image Download (PPT) View Large Image Figure Viewer Download Hi-res image Download (PPT) Abbreviations: Ad26, Ad26.COV2.S; BBIBP, BBIBP-CorV; BNT, BNT162b2; Covishield, ChAdOx1 nCoV-19 (Covishield); Gam, Gam-COVID-Vac; mRNA, mRNA-1273; Vaxzeria, ChAdOx1 nCoV-19 (Vaxzeria) Remarks: Yellow, Conventional inactivated vaccines (BBIBP-CorV [Sinopharm], CoronaVac [Sinovac]); Green, RNA vaccines (BNT162b2 [Pfizer
- |||||||||| COVIran Barekat / Barakat Pharma, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. (Pubmed Central) - Mar 15, 2023
Reactogenicities were less common after the second dose of the vaccines. The adverse effects of AZD1222 were greater than those of other vaccines.
- |||||||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Trial completion date: FH-63: Phase IIB Study of Recombinant Novel Coronavirus Vaccine (clinicaltrials.gov) - Mar 14, 2023
P2b, N=450, Active, not recruiting,
The adverse effects of AZD1222 were greater than those of other vaccines. Trial completion date: Jan 2023 --> Apr 2023
- |||||||||| CoronaVac / Sinovac, Bio Farma Indonesia, Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Neurological Manifestations Post-COVID-19 Vaccination: A Review of Case Studies (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3864;
Design/Methods A thorough literature search of Google Scholar and PubMed was conducted from December 2020 to October 2021, which included case reports of neurological complications with the following COVID-19 vaccines: Pfizer-BioNTech, Moderna, J&J/Janssen, AstraZeneca, Sinovac-CoronaVac, Sputnik V, and COVAXIN...Conclusions Several post-marketing CNS and PNS adverse events have occurred following the COVID-19 vaccination, including CVST, GBS, and TM. Further studies with non-vaccinated controls might help understand the pathophysiologic mechanisms of these neurological manifestations.
- |||||||||| Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm
Enrollment change, Trial primary completion date: CovicompareG: Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea (clinicaltrials.gov) - Feb 16, 2023
P2, N=200, Recruiting,
To enhance Africa's contribution to the global knowledge on COVID-19 vaccine safety, governments must explicitly consider safety monitoring as a priority, and funding organizations need to systematically and continuously support these programs. N=400 --> 200 | Trial primary completion date: Aug 2022 --> Aug 2023
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: T-Cell Immunity in COVID-19-Recovered Individuals and Individuals Vaccinated with the Combined Vector Vaccine Gam-COVID-Vac. (Pubmed Central) - Feb 12, 2023
release by single sensitized T-cells in response to specific stimulation in recovered and vaccinated individuals did not result in the accumulation of this and other cytokines in the culture medium. These findings suggest a balance between cytokine production and utilization by immunocompetent cells as a prerequisite for providing a controlled cytokine signal and avoiding a "cytokine storm".
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Retrospective data, Journal: Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study. (Pubmed Central) - Jan 28, 2023
Achieving and maintaining a high blood concentration of protective immune biomarkers that predict vaccine effectiveness is very critical to limit transmission and contain outbreaks. In this study, boosting with only one dose or with only BBIBP-CorV after priming with BBIBP-CorV was insufficient, whereas boosting with two doses, particularly boosting with the mRNA-based vaccine, was shown to be associated with having a high concentration of anti-S, anti-N, and neutralizing IgG antibodies and producing an efficient T-cell response.
- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Enrollment change, Trial completion date: The COVID-19 Back-to-Normal Study (clinicaltrials.gov) - Jan 17, 2023
P=N/A, N=2000, Active, not recruiting,
For the first time, it has been shown that a single booster dose of the Sputnik vaccine is sufficient to form a protective immunity in most vaccinees regardless of age and preexisting antibody level. N=1000 --> 2000 | Trial completion date: Apr 2023 --> Jan 2024
- |||||||||| Journal: Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population. (Pubmed Central) - Jan 6, 2023
Therefore, determining the effectiveness of these and the longevity of acquired immunity is extremely important in a scenario where SARS-CoV-2 circulation becomes endemic and booster doses are required periodically. Our data reveal significant differences both in the generation of antibodies as well as in their longevity for the vaccines applied in the country but suggest that, in general, the Mexican population can reach a high capacity to neutralize the virus, therefore, regarding less the variant for which they were designed.
- |||||||||| Journal, Adverse events: Safety and reported adverse effects of coronavirus disease -2019 (COVID-19) vaccines in patients with rheumatic diseases. (Pubmed Central) - Jan 5, 2023
In patients, BBIBP-CorV (Sinopharm) was the most frequent vaccine 42.3% (n=52); CoronaVac (Sinovac) 22% (n=27); ChAdOx1 (AstraZeneca) 17.9% (n=22); BNT162 (Pfizer BioNTech) 14.6% (n=18); Sputnik V 1.6% (n=2) and Ad26.COV2-S (Johnson & Johnson) 1.6% (n=2)...ChAdOx1 (AstraZeneca) had the highest incidence of side effects, mRNA1273 (Moderna) showed the lowest. COVID-19 vaccine was effective in decreasing infection and disease severity in RDs patients and control, with similar, mild adverse effects.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal, Adverse events: Personalized predictions of adverse side effects of the COVID-19 vaccines. (Pubmed Central) - Jan 5, 2023
Using a large cohort of recipients vaccinated with COVID-19 vaccines, a novel and personalized strategy was established to predict the occurrence of the most common adverse side effects with high accuracy. This technique can serve as a tool to inform COVID-19 vaccine selection and generate personalized factsheets to curb concerns about adverse side effects.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Effects of COVID-19 on the Course of Epilepsy. (Pubmed Central) - Dec 29, 2022
These results will help practicing physicians determine management tactics in epilepsy patients. Continuation of this research on the effects of COVID-19 disease and vaccination on the dynamics of epilepsy in a larger cohort is needed.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Relapse of lupus nephritis in temporal association with anti SARS-CoV-2 vaccination (Pubmed Central) - Dec 27, 2022
After treatment with prednisone (20 y 10 mg/day in case 1 and 2, respectively) and an increased dose of mycophenolate (from 1.5 g/day to 2.0 g/dayand 1.08 to 1.44 g/día of sodic mycophenolate in case 1 y 2, respectively) both patients regained renal remission. These cases are of relevance as they introduce a possible association between the different anti-SARS-CoV-2 vaccine platforms and SLE flares; at the same time to suggest the need for close control in the post vaccination period in this population of patients.
|
